FOLH1 and prostate carcinoma: The strategy consisted in addressing the tumor trough PSMA, a protein overexpressed in the surface of prostate cancer cells and tumor vascular endothelium, with a PSMA aptamer linked to PLK-1 and BCL-2 siRNAs.